1.94
0.02 (1.04%)
| Previous Close | 1.92 |
| Open | 1.92 |
| Volume | 232,617 |
| Avg. Volume (3M) | 1,042,190 |
| Market Cap | 103,720,744 |
| Price / Sales | 77.32 |
| Price / Book | 4.96 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Diluted EPS (TTM) | -0.770 |
| Total Debt/Equity (MRQ) | 416.80% |
| Current Ratio (MRQ) | 4.66 |
| Operating Cash Flow (TTM) | -33.87 M |
| Levered Free Cash Flow (TTM) | -19.45 M |
| Return on Assets (TTM) | -41.29% |
| Return on Equity (TTM) | -307.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Milestone Pharmaceuticals Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | 0.75 |
|
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.71% |
| % Held by Institutions | 22.25% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Propel Bio Management, Llc | 31 Mar 2025 | 1,451,557 |
| Alta Fundamental Advisers Llc | 31 Mar 2025 | 1,427,479 |
| Simplify Asset Management Inc. | 31 Mar 2025 | 850,000 |
| Lion Point Capital, Lp | 31 Mar 2025 | 548,806 |
| 52 Weeks Range | ||
| Median | 5.00 (157.73%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 05 Jun 2025 | 5.00 (157.73%) | Buy | 1.74 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Jul 2025 | Announcement | Milestone Pharmaceuticals Announces Proposed Public Offering |
| 11 Jul 2025 | Announcement | Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray |
| 11 Jul 2025 | Announcement | Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants |
| 16 Jun 2025 | Announcement | Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting |
| 28 May 2025 | Announcement | Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference |
| 14 May 2025 | Announcement | Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |